Financial News

Resilience Receives USD $164 Million Investment from the Government of Canada to Modernize and Expand Its Ontario Biomanufacturing Site, Improving Pandemic Preparedness

Products You May Like

Article content material

SAN DIEGO & BOSTON — Nationwide Resilience, Inc. (Resilience), an organization constructing the world’s most superior biopharmaceutical manufacturing ecosystem, introduced that the Authorities of Canada will make investments CAD 199.2 million ($163.8 million), via the Strategic Innovation Fund, within the firm’s Ontario-based subsidiary Resilience Biotechnologies Inc. (RBI) to modernize and increase manufacturing capability.

This undertaking will assist enhance manufacturing capability for vaccines and therapeutics, together with novel applied sciences reminiscent of mRNA that are actually getting used to combat COVID-19. The enlargement will construct on RBI’s present strengths as an necessary biomanufacturing group in Canada, sustaining 295 present jobs and create 205 new full-time positions on the Mississauga facility.

“Resilience was based throughout the pandemic to construct a greater system for manufacturing advanced medicines to combat lethal illnesses,” mentioned Rahul Singhvi, Sc.D, Chief Government Officer of Resilience. “This partnership with the Authorities of Canada will assist put together Canada for future pandemics and strengthen the nation’s biopharmaceutical ecosystem.”

Article content material

“The Authorities of Canada’s prime precedence is to guard the well being and security of Canadians. Right this moment’s contribution to Resilience Biotechnologies Inc. is one other necessary step to help Canada’s management within the life sciences sector and to construct future pandemic preparedness. These investments are additionally creating well-paying jobs and serving to to develop Canada’s life sciences ecosystem as an engine for our financial restoration.” – The Honourable François-Philippe Champagne, Minister of Innovation, Science and Business

RBI, situated in Mississauga, is a 136,000 sq ft (12,800 m2) biomanufacturing facility that presently supplies course of and analytical growth, scale up, drug substance and drug product / fill end manufacturing for quite a lot of medicines.

About Resilience

Resilience (Nationwide Resilience, Inc.) is a first-of-its-kind manufacturing and expertise firm devoted to broadening entry to advanced medicines and defending biopharmaceutical provide chains towards disruption. Based in 2020, the corporate is constructing a sustainable community of high-tech, end-to-end manufacturing options to make sure the medicines of at this time and tomorrow will be made shortly, safely, and at scale. Resilience provides the best high quality and regulatory capabilities, and versatile and adaptive amenities to serve companions of all sizes. By constantly advancing the science of biopharmaceutical manufacturing and growth, Resilience frees companions to deal with the discoveries that enhance sufferers’ lives.

For extra data, go to

View supply model on



Ryan Flinn
Head of Communications

Products You May Like